Brontictuzumab (INN; development code OMP-52M51) is a humanized monoclonal antibody designed for the treatment of cancer.Statement On A Nonproprietary Name Adopted By The USAN Council - Brontictuzumab, American Medical Association.
It blocks the NOTCH1 receptor.
This drug was developed by OncoMed Pharmaceuticals.
References